INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Duty Stuart reported FHTX

Director · Foghorn Therapeutics Inc. · Foghorn Therapeutics Inc. — Stock Options (Right to buy)

Side
A
Value
$114K
Shares
28.0K
Price
$4.08
Executed
Jun 24, 2026
Disclosed
Jun 25, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 24 executedJun 25, 2026 disclosed

FHTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
12/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+4 / 25

$114K reported value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FHTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    12
    GN
    Gallagher NeilDirector
    FHTXFoghorn Therapeutics Inc.
    Grant or award
    		A$114K
    28.0K sh
    		Jun 24, 2026Jun 25, 2026
    traded Jun 24, 2026
    		+1dSEC FORM 4

    Evidence

    20
    GA
    Gottschalk AdrianDirector, Chief Executive Officer
    FHTXFoghorn Therapeutics Inc.
    Gift
    		G—
    59.2K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    20
    GA
    Gottschalk AdrianDirector, Chief Executive Officer
    FHTXFoghorn Therapeutics Inc.
    Gift
    		G—
    47.5K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    20
    GA
    Gottschalk AdrianDirector, Chief Executive Officer
    FHTXFoghorn Therapeutics Inc.
    Gift
    		G—
    59.2K sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    12
    GA
    Gottschalk AdrianDirector, Chief Executive Officer
    FHTXFoghorn Therapeutics Inc.
    Gift
    		G—
    47.5K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    18
    GA
    Gottschalk AdrianDirector, Chief Executive Officer
    FHTXFoghorn Therapeutics Inc.
    Grant or award
    		A$5.62M
    1.07M sh
    		Feb 5, 2026Feb 6, 2026
    traded Feb 5, 2026
    		+1dSEC FORM 4

    Evidence

    15
    RA
    Rivkin AnnaChief Business Officer
    FHTXFoghorn Therapeutics Inc.
    Grant or award
    		A$942K
    165.0K sh
    		Jan 30, 2026Feb 2, 2026
    traded Jan 30, 2026
    		+3dSEC FORM 4

    Evidence

    18
    CC
    Costa CarlosChief People Officer
    FHTXFoghorn Therapeutics Inc.
    Grant or award
    		A$1.31M
    230.0K sh
    		Jan 30, 2026Feb 2, 2026
    traded Jan 30, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001970274-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 24, 2026
    Published
    Jun 25, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Duty Stuart
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Foghorn Therapeutics Inc. — Stock Options (Right to buy)
    Ticker
    FHTX
    Shares
    28.0K
    Price per share
    $4.08
    Value
    $114,240
    Execution date (reported)
    Jun 24, 2026
    Owned after transaction
    28.0K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 28.0K
    • Price: $4.08

    = $114,240

    What this establishes

    Duty Stuart filed this Form 4 reporting a grant or award of FHTX on Jun 24, 2026. It became public on Jun 25, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Duty Stuartcik:0001970274
    Issuer
    Foghorn Therapeutics Inc.cik:0001822462

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.